Research programme: drug discovery - Actelion

Drug Profile

Research programme: drug discovery - Actelion

Alternative Names: Actelion-4; Actelion-5; Actelion-6; Actelion-7

Latest Information Update: 27 Jun 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Actelion Pharmaceuticals
  • Class
  • Mechanism of Action Aspartic endopeptidase modulators; Ion channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cardiovascular disorders; CNS disorders; Immunological disorders
  • Research Cancer; Infections

Most Recent Events

  • 16 Jun 2017 Actelion Pharmaceuticals has been acquired by Janssen Pharmaceuticals
  • 02 Feb 2017 Preclinical research in Immunological disorders is still ongoing in Switzerland
  • 23 Jan 2017 Actelion Pharmaceuticals and Enamine enter into a collaboration agreement for the discovery and development of therapies for cardiovascular, central nervous system and immunological disorders, infectious diseases and cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top